- Home
- PROP vs IMUX Comparison
PROP vs IMUX Comparison
Compare PROP & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PROP | IMUX |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.6M | 85.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PROP | IMUX |
|---|---|---|
| Price | $1.73 | $0.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $6.75 | $6.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $166,577,000.00 | N/A |
| Revenue This Year | $3,967.26 | N/A |
| Revenue Next Year | $71.16 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.64 | $0.55 |
| 52 Week High | $10.58 | $1.39 |
Technical Indicators
Market Signals| Indicator | PROP | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 45.73 | 39.12 |
| Support Level | $1.65 | $0.55 |
| Resistance Level | $1.77 | $0.70 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 28.26 | 34.08 |
Price Performance
Historical ComparisonAbout PROP Prairie Operating Co.
Prairie Operating Co is a Houston-based independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. The Company's assets and operations are concentrated in the oil and liquids-rich regions of the Denver-Julesburg (DJ) Basin, with a focus on the Niobrara and Codell formations. The Company is committed to the responsible development of its oil and natural gas resources and is focused on maximizing returns through consistent growth, capital discipline, and sustainable cash flow generation.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.